Literature DB >> 1397318

A long-lived state for influenza virus-erythrocyte complexes committed to fusion at neutral pH.

C Schoch1, R Blumenthal, M J Clague.   

Abstract

The low pH-induced fusion of influenza virus with intact erythrocyte plasma membranes is preceded by a delay time following pH reduction, that is itself pH- and temperature dependent. At 37 degrees C/pH 4.8, lipid mixing between virus and target membranes begins < 2 s after pH reduction, whereas at 4 degrees C/pH 4.8, fusion does not commence until > 10 min after pH reduction. We have found that within this time period at 4 degrees C, a population of virus acquires the capacity to subsequently undergo fusion with high efficiency at elevated temperatures and pH 7.4. Both the kinetics and the extent of this pH 7.4 fusion depend upon the time of pre-incubation at pH 4.8/4 degrees C. Incubation at pH 7.4/4 degrees C, following this pre-incubation does not result in fusion, but the capacity to fuse at pH 7.4/37 degrees C is retained for a time period exceeding 1 h. The longevity of this fusion committed state makes it amenable to biochemical and immunological analysis. We have shown that it is insensitive to dithiothreitol, neuraminidase and trypsin, but is incapacitated by thermolysin or protease K. We conclude that only the HA2 sub-unit of influenza haemagglutinin is a necessary protein component of later stages of the fusion pathway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397318     DOI: 10.1016/0014-5793(92)81107-w

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Evolution of intermediates of influenza virus hemagglutinin-mediated fusion revealed by kinetic measurements of pore formation.

Authors:  R M Markosyan; G B Melikyan; F S Cohen
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

2.  Conformational intermediates and fusion activity of influenza virus hemagglutinin.

Authors:  T Korte; K Ludwig; F P Booy; R Blumenthal; A Herrmann
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Reversible merger of membranes at the early stage of influenza hemagglutinin-mediated fusion.

Authors:  E Leikina; L V Chernomordik
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

4.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Genetic control of fusion pore expansion in the epidermis of Caenorhabditis elegans.

Authors:  Tamar Gattegno; Aditya Mittal; Clari Valansi; Ken C Q Nguyen; David H Hall; Leonid V Chernomordik; Benjamin Podbilewicz
Journal:  Mol Biol Cell       Date:  2007-01-17       Impact factor: 4.138

6.  pH-dependence of intermediate steps of membrane fusion induced by the influenza fusion peptide.

Authors:  Ding-Kwo Chang; Shu-Fang Cheng
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

7.  Role of endocytosis and low pH in murine hepatitis virus strain A59 cell entry.

Authors:  Patricia Eifart; Kai Ludwig; Christoph Böttcher; Cornelis A M de Haan; Peter J M Rottier; Thomas Korte; Andreas Herrmann
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  Enhancement of viral fusion by nonadsorbing polymers.

Authors:  A Herrmann; M J Clague; R Blumenthal
Journal:  Biophys J       Date:  1993-07       Impact factor: 4.033

9.  A mechanism of protein-mediated fusion: coupling between refolding of the influenza hemagglutinin and lipid rearrangements.

Authors:  M M Kozlov; L V Chernomordik
Journal:  Biophys J       Date:  1998-09       Impact factor: 4.033

10.  Inner/Outer nuclear membrane fusion in nuclear pore assembly: biochemical demonstration and molecular analysis.

Authors:  Boris Fichtman; Corinne Ramos; Beth Rasala; Amnon Harel; Douglass J Forbes
Journal:  Mol Biol Cell       Date:  2010-10-06       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.